Q4 FY26 Quarterly Investor Presentation & Webinar

• Strong Q4 Core Testing Growth +54% YoY volume.
• Full group break-even on run-rate basis in CY2027.
• On track to launch GI Navigator, a new category-defining testing product, in September 2026.
• Active partnering for pipeline of therapeutic assets backed by big-data, preclinical and clinical validation.

Microba Life Sciences Ltd has announced its Q4 FY26 results, highlighting significant growth in core testing volume, up 54% YoY. The company also reported a 78% YoY increase in core testing volume and a 92% YoY increase in revenue for FY26. Microba's enterprise account adoption in Australia has grown, with 43 accounts signed and over 5,600 tests sold, up 87% QoQ. The company is on track to launch its new product, GI Navigator, in September 2026, which is expected to expand its market reach. Microba's supplement business, Invivo, saw a 11% QoQ increase in revenue to $0.75m in Q4. The company is also focusing on its therapeutics division, which has a rich pipeline of live biotherapeutic assets. Microba anticipates full group break-even on a run-rate basis in CY2027.

Full group break-even on run-rate basis in CY2027

Microba anticipates continued growth in test sales and clinical adoption in Australia and the United Kingdom, with the upcoming launch of GI Navigator in Q4 FY26.